APA (7th ed.) Citation

Wang, Q., Xu, A., Ma, C., Wang, T., Liu, P., Duan, Y., . . . Chen, H. (2023). 1487P Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer: Updated results. Annals of Oncology, 34, S840. https://doi.org/10.1016/j.annonc.2023.09.2518

Chicago Style (17th ed.) Citation

Wang, Q., et al. "1487P Real-world Efficacy and Safety of Anlotinib in Combination with PD-1/PD-L1 Inhibitors as First-line or Second-line Treatment in Advanced Non-small Cell Lung Cancer: Updated Results." Annals of Oncology 34 (2023): S840. https://doi.org/10.1016/j.annonc.2023.09.2518.

MLA (9th ed.) Citation

Wang, Q., et al. "1487P Real-world Efficacy and Safety of Anlotinib in Combination with PD-1/PD-L1 Inhibitors as First-line or Second-line Treatment in Advanced Non-small Cell Lung Cancer: Updated Results." Annals of Oncology, vol. 34, 2023, p. S840, https://doi.org/10.1016/j.annonc.2023.09.2518.